https://scholars.lib.ntu.edu.tw/handle/123456789/526395
標題: | Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols ??A single institution report in Taiwan | 作者: | SHU-WEI CHOU HSIU-HAO CHANG MENG-YAO LU YUNG-LI YANG Lin D.-T. Lin K.-H. SHIANN-TANG JOU |
公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 期: | 1P2 | 起(迄)頁: | 332-340 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background: Taiwan Pediatric Oncology Group (TPOG) initiated two consecutive protocols for treating pediatric patients with rhabdomyosarcoma since 1995. However, the results have not been analyzed and reported yet. The aim of this study is to investigate the treatment results of these two protocols in our hospital and to assess whether the results are comparable to other large-scaled studies. Methods: Treatment of pediatric patients with rhabdomyosarcoma according to TPOG protocols at National Taiwan University Hospital began in 1995. Between 1995 and 2006, patients were treated by TPOG RMS 95 protocol, which was based on IRS-III/IV. After 2007, patients were treated by TPOG RMS 2007 protocol which was adapted from IRS-V study. The clinical data of patients were obtained retrospectively by reviewing medical records. The date of the latest follow-up was December 31, 2016. Results: Thirty-seven patients were enrolled in this study. The 5-year overall survival (OS) and event-free survival rates of them were 54.7 ± 8.8% and 48.5 ± 8.6%, respectively. The 5-year OS rates for patients treated by TPOG RMS 95 and TPOG RMS 2007 protocols were 55.0 ± 11.1% and 55.9 ± 14.0%, respectively. Age at diagnosis of less than ten years old and receiving operation with gross total or subtotal tumor resection were identified as independent prognostic factors that predicted better outcomes in the multivariate analysis. Conclusion: The clinical outcomes of pediatric patients with rhabdomyosarcoma in Taiwan improved dramatically after incorporating two consecutive protocols from TPOG. In addition, the treatment results of these two protocols were comparable to large-scale studies of other countries. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048304287&doi=10.1016%2fj.jfma.2018.05.015&partnerID=40&md5=bc88b0060f0e07b60e7dd69b749b5659 https://scholars.lib.ntu.edu.tw/handle/123456789/526395 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.05.015 | SDG/關鍵字: | age; Article; cancer surgery; cancer survival; child; clinical article; clinical outcome; clinical protocol; event free survival; female; follow up; human; male; medical record; overall survival; pediatric patient; retrospective study; rhabdomyosarcoma; survival rate; Taiwan; adolescent; epidemiology; infant; mortality; multimodality cancer therapy; multivariate analysis; newborn; pathology; preschool child; procedures; prognosis; rhabdomyosarcoma; survival analysis; antineoplastic agent; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Infant, Newborn; Male; Multivariate Analysis; Prognosis; Retrospective Studies; Rhabdomyosarcoma; Survival Analysis; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。